Patient safety kidney transplantation

Safety and Tolerability Study of Inhaled Carbon Monoxide in Kidney Transplant Patients http //www.clinicaltrials.gov/ct2/show/NCT00531856. Accessed 16 Feb 2010... 

Navascues RA, Gomez E, Rodriguez M, Laures AS, Baltar J, Grande JA Safety of the allop-urinol-mycophenolate mofetil combination in the treatment of hyperuricemia of kidney transplant patients. Nephron (2002) 91,173-4. 

Organ transplants The safety and efficacy of peginterferon alfa-2b alone or in combination with ribavirin capsules for the treatment of hepatitis C in patients who have received liver or other organ transplants have not been studied. Preliminary data indicate that interferon alpha therapy may be associated with an increased rate of kidney graft rejection. Liver graft rejection also has been reported, but a causal... 

First MR. An update on new immunosuppressive drugs undergoing preclinical and clinical trials potential applications in organ transplantation. Am J Kidney Dis 1997 29(2) 303-17. Birck R, Warnatz K, Lorenz HM, Choi M, Haubitz M, Grunke M, Peter HH, Kalden JR, Gobel U, Drexler JM, Hotta O, Nowack R, Van Der Woude FJ. 15-Deoxyspergualin in patients with refractory ANCA-associated systemic vasculitis a six-month open-label trial to evaluate safety and efficacy. J Am Soc Nephrol 2003 14(2) 440-7. 

Anti-thymocyte globulin (ATG, thymoglobulin) is a polyclonal rabbit antithymocyte globulin that has been used as an immunosuppressive agent in kidney and hver transplant patients. Despite a fairly high safety profile, reported side effects of ATG include hypertension, leucopenia and ARDS [109]. Renal adverse effects are extremely rare only two case reports describe the occurrence of acute renal failure in patients treated with ATG [110, 111]. Cessation of ATG therapy in both cases and plasmapheresis in one case resulted in full recovery. 

---